Cardiac amyloidosis future or investigational therapies: Difference between revisions
| Line 13: | Line 13: | ||
* CPHPC | * CPHPC | ||
CPHPC also called R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid is a competitive inhibitor of SAP binding to amyloid fibrils. CPHPC is a [[proline]]-derived small molecule able to strip amyloid P (AP) from deposits by reducing levels of circulating [[ | CPHPC also called R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid is a competitive inhibitor of SAP binding to amyloid fibrils. CPHPC is a [[proline]]-derived small palindromic molecule able to strip amyloid P (AP) from deposits by reducing levels of circulating [[serum amyloid protein]] (SAP). It also crosslinks and dimerizes SAP, which is cleared rapidly by the [[liver]]. The SAP-amyloid association has also been identified as a possible drug target for anti-amyloid therapy, with the recent development and first stage clinical trials of CPHPC for [[amyloidosis]].<ref name="pmid12015594">{{cite journal| author = Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN | title = Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis | journal = Nature | volume = 417 | issue = 6886 | pages = 254–9 | year = 2002 | pmid = 12015594 | doi = 10.1038/417254a }}</ref> | ||
==References== | ==References== | ||
Revision as of 17:05, 12 May 2013
|
Cardiac amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cardiac amyloidosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Cardiac amyloidosis future or investigational therapies |
|
FDA on Cardiac amyloidosis future or investigational therapies |
|
CDC onCardiac amyloidosis future or investigational therapies |
|
Cardiac amyloidosis future or investigational therapies in the news |
|
Blogs on Cardiac amyloidosis future or investigational therapies |
|
Risk calculators and risk factors for Cardiac amyloidosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]; Aarti Narayan, M.B.B.S [3]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
New therapies targeting the serum amyloid protein (SAP), which is an excellent immunogen and a universal component of all amyloid deposits, using monoclonal antibodies are currently being investigated.
Future and Investigational Therapies
Possible future treatment options which are currently being investigated include:
- Anti-SAP antibody
- CPHPC
CPHPC also called R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid is a competitive inhibitor of SAP binding to amyloid fibrils. CPHPC is a proline-derived small palindromic molecule able to strip amyloid P (AP) from deposits by reducing levels of circulating serum amyloid protein (SAP). It also crosslinks and dimerizes SAP, which is cleared rapidly by the liver. The SAP-amyloid association has also been identified as a possible drug target for anti-amyloid therapy, with the recent development and first stage clinical trials of CPHPC for amyloidosis.[1]
References
- ↑ Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN (2002). "Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis". Nature. 417 (6886): 254–9. doi:10.1038/417254a. PMID 12015594.